Drugs / SEL-110.36
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04596540 | Nov 2020 → Jan 2023 | gout | Swedish Orphan Biovitrum | Completed | No outcome recorded |
| Phase 3 | NCT04513366 | Aug 2020 → Jul 2022 | gout | Swedish Orphan Biovitrum | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEL-110.36 | “Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR” NCT04596540 ↗1“SEL-110.36, ImmTOR” NCT04513366 ↗ |
| Known as | ImmTOR | “Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR” NCT04596540 ↗1“SEL-110.36, ImmTOR” NCT04513366 ↗ |
| Known as | SEL-110 | “Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR” NCT04596540 ↗ |
| Route | Intravenous | “via IV infusion” NCT04513366 ↗ |